NDLTD logo NDLTD Union Catalog and Global ETD Search

Global ETD Search

Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.

Results

Showing 1 to 20 of 48 for “"L-DOPA"”.

  1. L-dopa metabolism and the regulation of brain polysome aggregation

    Weiss, Bette Fishman.Massachusetts Institute of Technology1972

    Intraperitoneal administration of L-dopa {50-300 mg/kg) caused a marked disaggregation of brain polysomes in immature rats {15-20 g body weight). Polysome disaggregation was maximal between 40 and 60 minutes after injection and not significant at 20 and 120 minutes. Older rats {50 and 100 g body …

    mit Repository record

  2. Modification of Aplysia Feeding Network By L-Dopa and Dopamine-Dependent Learning

    Neveu, Curtis, Neveu, Curtis L, <p>0000-0003-3291-7537</p>2018

    <p>Dopamine (DA) is a ubiquitous neuromodulator of neuronal networks in the animal kingdom and has a well-established role in modulating motor behavior and encoding reward information. Although the effects of DA and DA-dependent learning at the behavioral and molecular levels are well-understood, …

    uthsc Repository record

  3. Development and Optimisation of Nanoparticulate System for Brain Delivery of L-DOPA

    Zhou, YongResearchSpace@Auckland2012

    … morbidity and a shortened life span. L-DOPA (LD) is the primary drug used for the treatment of PD. However, only 1% of the given dose is transported unchanged to the central nervous system (CNS) after oral administration due to its peripheral decarboxylation. As a result, LD has to be …

    auckland-ms Repository record

  4. Comparative analysis of Anopheles gambiae L-tyrosine decarboxylase and L-DOPA decarboxylase

    Aljabri, Hareb MohammedVirginia Tech2010

    A major pathway of tyramine and dopamine synthesis in insects is through the decarboxylation of tyrosine and DOPA, respectively. Although tyrosine decarboxylase (TDC) has been mentioned in some reports, it has never been critically analyzed. The high sequence identity shared by tyrosine …

    vt Repository record

  5. L-DOPA production in a liquid membrane enzyme reactor: process development and modeling

    Simmons, Donald KarlGeorgia Institute of Technology1990

    Opened per request of the author, 7/8/2026. See libanswers ticket https://libanswers.library.gatech.edu/admin/ticket?qid=18631263

    gatech Repository record

  6. Μελέτη της έκφρασης και ρύθμισης της L-Dopa Αποκαρβοξυλάσης σε Bιοχημικούς μηχανισμούς Νευροεκφυλισμού

    ΔΗΜΗΤΡΙΟΥ ΑΦΡΟΔΙΤΗ, DIMITRIOU AFRODITI2026

    … τώρα έχει δείξει με τη μελέτη του μορίου της L-DOPA αποκαρβοξυλάσης ότι συμμετέχει τόσο στον αποπτωτικό θάνατο όσο και σε διεργασίες κυτταροτοξικότητας . Πρόσφατα δεδομένα της ερευνητικής μας ομάδας, έδειξαν τη σχέση της έκφρασης της L-DOPA αποκαρβοξυλάσης με την οξειδωτική καταπόνηση. Ακόμη και …

    athens Repository record

  7. Therapeutische Wirksamkeit von L-Dopa bei Amyotropher Lateralsklerose - eine Analyse von 50 therapeutischen Heilversuchen

    Göldner, AlexanderUniversität Ulm

    ulm-diss Repository record

  8. The Effect of L-DOPA and Natural Products on Age-Related Motor Deficits and Dopaminergic Cell Survival

    Allen, Erika Nicole2018

    … for age-related motor deficits. However, L-DOPA is used for motor dysfunction in Parkinson's disease (PD). Therefore, we investigated the effect of L-DOPA on motor deficits in young (2 mo) and old (20 mo) mice. We found that L-DOPA reversed age-related motor decline.</p><p> Chronic L-DOPA …

    duquesne Repository record

  9. Differential Effects of Parkinsonian Toxins and L-DOPA on Locus Coeruleus and Substantia Nigra Neurons: Implications for Parkinson’s Disease

    Yee, AndrewResearchSpace@Auckland2015

    … motor symptoms, caused by degeneration of dopamine (DA)-producing neurons of the Substantia Nigra pars compacta (SNc). However, PD patients also suffer from many non-motor symptoms (NMS; eg. sleep disturbance, autonomic dysfunction, depression and anxiety), which cause significant …

    auckland-ms Repository record

  10. ΑΠΟΜΟΝΩΣΗ ΚΑΙ ΚΑΘΑΡΙΣΜΟΣ ΤΟΥ ΕΝΖΥΜΟΥ L-DOPA ΑΠΟΚΑΡΒΟΞΥΛΑΣΗ ΑΠΟ ΤΙΣ ΛΕΥΚΕΣ ΝΥΜΦΕΣ ΤΟΥ ΕΝΤΟΜΟΥ CERATITIS CAPITATA ΚΑΙ ΑΠΟ ΑΝΘΡΩΠΙΝΟ ΝΕΦΡΙΚΟ ΙΣΤΟ. ΣΥΓΚΡ...

    Μαππούρας, ΔημήτριοςΕθνικό και Καποδιστριακό Πανεπιστήμιο Αθηνών (ΕΚΠΑ)1990

    L-DOPA DECARBOXYLASE IS A PYRIDOXAL PHOSPHATE-DEPENDENT ENZYME CATALYZING THE DECARBOXYLATION OF CERTAIN AROMATIC AMINO ACIDS TO THEIR RESPECTIVE AMINES. SINCE DOPAMINE IS INVOLVED IN MANY IMPORTANT METABOLIC PROCESSES PLAYING A CENTRAL ROLE IN THE PATHOGENESIS OF CERTAIN NEUROLOGICAL DISORDERS AND …

    greece Repository record

  11. Effects of the Administration of 5-Hydroxydl-Tryptophan and 3,4-Dihydroxyphenylalanine on the Acquisition of a Conditioned Avoidance Response

    Percy, HectorDrake University1974

    … administration of 3,4-dihydroxyphenylalanine (L-Dopa) has been shown to result in the facilitation of performance while the administration of 5-hydroxytryptophan (5-HTP) results in an impairment of performance and reported enhancement of acquisition. The purpose of the present study is to compare …

    drake Repository record

  12. Two Sides of The Same Coin in The Levodopa Treatment of Parkinson's Disease

    신, 진영2011

    … PD is a characterized by selective loss of dopaminergic neurons in the pars compacta of the substantia nigra. Levodopa (L-dopa) and dopamine agonists have been most commonly used for symptomatic treatment. Since its initial introduction in 1967, L-dopa has been shown to be the most effective …

    ajou Repository record

  13. Therapeutic strategies of Parkinson's disease: Alternative dopamine replacement and potential drug targets

    Abdalla , Ahmed AbdulrahmanIowa State University2022

    … movement impairment and cognitive decline. Dopamine deficiency resulting from dopaminergic neuronal degeneration in substantia nigra (SN), known to be linked to mitochondrial dysfunction, ultimately manifests as the cardinal extrapyramidal motor symptoms of rigidity, bradykinesia, tremors, …

    iastate Repository record

  14. Pitx3Null Mutant (Striatal Dopamine-Deficient) Mice Have Exaggerated Spiny Projection Neuron Responses to l-DOPA and D1 Agonism and Lack Baseline Striatonigral Spiking

    Sagot, Ben2018

    <p>L-3,4 dihidroxyphenylalanine (l-DOPA) strongly stimulates motor activity in parkinsonian patients and animal models of Parkinson's disease. Severe striatal dopamine (DA) loss characterizes Parkinson's disease and its animal models. Given the canonical rate model of Parkinson's Disease …

    tenn-hsc Repository record

  15. Influence of Long-term Intermittent L-DOPA Administration upon Therapeutic Responses in Animal Models of Parkinson's Disease: Study with Forepaw Adjusting Step Test

    이, 은아2011

    Doctor

    ajou Repository record

  16. A behavioural evaluation of the potential of nNOS inhibitors to control dyskinesia in animal models of Parkinson’s disease

    Hirsch, TamaraKing's College London2012

    Long-term dopaminergic therapy in Parkinson’s disease (PD) can lead to motor complications including dyskinesia which can be treated with amantadine, an N-methyl-D-aspartate (NMDA) receptor antagonist. NMDA receptor activation is linked with nitric oxide (NO) production and changes in synaptic …

    kings Repository record

  17. Striatal Dopamine Release by Serotonergic Terminals in the Dopamine-Depleted Rat

    Rau, Kristi Suzanne

    <p>Parkinson’s disease (PD) results from severe dopamine (DA) neuron loss within the substantia nigra pars compacta. In an effort to replace the diminished DA levels, L-dopa, the precursor of DA, is administered. Although the most commonly prescribed medication, the site(s) where L-dopa is …

    loma-linda Repository record

  18. Investigating the role of neuroinflammation in a mouse model of L-Dopa induced dyskinesia and exploring the anti-dyskinetic potential of a cannabinoid receptor agonist

    Rentsch, PeggyUNSW, Sydney2019

    … has also been implicated in the development of L-Dopa induced dyskinesia (LID), a PD side effect that arises with chronic L-Dopa treatment. This thesis had two major aims; First, we aimed to characterize the neuroinflammatory phenotype present in a mouse model of PD and LID. Second, we aimed to …

    unsw Repository record

  19. Der Einfluss von L-DOPA in Kombination mit physiotherapeutischer Behandlung auf die neuronale Plastizität (kortikale und subkortikale Reorganisation) in den intrazerebralen motorischen Zentren nach Schlaganfall

    Schaal, Matthias CorneliusUniversität Ulm

    ulm-diss Repository record

  20. Towards a Better Treatment of Parkinson's disease

    Karain, Bradley Darryl

    … the best current pharmacological therapy, L-DOPA, carries important clinical benefits, partly by reducing the dose-related side-effects which occur after five to ten years of use. Thus the central aim of this proposal is to determine whether low doses of a D2 antagonist may, by selectively …

    loma-linda Repository record

Page 1 of 3